On 12 September 2024, Merck (known as MSD outside the US and Canada) announced that Health Canada has approved Keytruda® (pembrolizumab) as monotherapy for treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prior treatment and which have no satisfactory alternative treatment options.
Keytruda® was first approved in Canada in 2015 and has numerous cancer indications (alone or in combination) including melanoma, bladder cancer, gastric cancer, and adenocarcinoma.